Ivan Griffin

Founder at BENEVOLENTAI S.A.

50 year

Commercial Services

Technology Services

Consumer Services

Profile

Ivan Griffin was the founder of BenevolentAI Ltd., founded in 2015, where the title held was Senior Vice President-Partnerships.
Dr. Griffin is the founder of BenevolentAI SA, founded in 2013, holding the title of Chief Business Officer.
Dr. Griffin is currently Director at BenevolentAI Cambridge Ltd. since 2019.
Former jobs include Secretary & Director at Cerogenix Ltd. from 2005 to 2007, Director at Sirigen Group Ltd., Principal at IP Group Plc, and Investment Manager at Nesta Investment Management LLP from 2009 to 2014.
Education includes undergraduate and doctorate degrees from the University of Oxford.

Ivan Griffin active positions

Companies	Position	Start
BENEVOLENTAI S.A.	Founder	01/11/2013
BenevolentAI Cambridge Ltd. BenevolentAI Cambridge Ltd. Miscellaneous Commercial ServicesCommercial Services Provides research and development services to pharmaceutical companies in the areas of Parkinsons disease and other neurodegenerative disorders	Director/Board Member	29/05/2019

All active positions of Ivan Griffin

Former positions of Ivan Griffin

Companies	Position	End
Nesta Investment Management LLP Nesta Investment Management LLP Investment ManagersFinance Nesta Investments invests in companies located in the United Kingdom. The firm targets companies operating across a broad range of sectors and industries. It provides financing for seed and early stage capital requirements with an investment size ranging from GBP 0.15 to 2 million and also makes follow-on investments.	Private Equity Investor	01/01/2014
Cerogenix Ltd. Cerogenix Ltd. Miscellaneous Commercial ServicesCommercial Services Provides pharmaceutical research and development services	Director/Board Member	24/08/2007
BenevolentAI Ltd. BenevolentAI Ltd. Packaged SoftwareTechnology Services Operates as a AI-enabled drug discovery company	Founder	-
Sirigen Group Ltd. Sirigen Group Ltd. Chemicals: Major DiversifiedProcess Industries Develops polymer dyes used in flow cytometry	Director/Board Member	-
IP GROUP PLC	Corporate Officer/Principal	-

See the detail of Ivan Griffin's experience

Training of Ivan Griffin

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Ivan Griffin's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	8
University of Oxford University of Oxford Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
IP Group Plc IP Group Plc Miscellaneous Commercial ServicesCommercial Services Operates as an intellectual property commercialization and venture capital fund management company	Commercial Services
BenevolentAI Cambridge Ltd. BenevolentAI Cambridge Ltd. Miscellaneous Commercial ServicesCommercial Services Provides research and development services to pharmaceutical companies in the areas of Parkinsons disease and other neurodegenerative disorders	Commercial Services
Cerogenix Ltd. Cerogenix Ltd. Miscellaneous Commercial ServicesCommercial Services Provides pharmaceutical research and development services	Commercial Services
Sirigen Group Ltd. Sirigen Group Ltd. Chemicals: Major DiversifiedProcess Industries Develops polymer dyes used in flow cytometry	Process Industries
Nesta Investment Management LLP Nesta Investment Management LLP Investment ManagersFinance Nesta Investments invests in companies located in the United Kingdom. The firm targets companies operating across a broad range of sectors and industries. It provides financing for seed and early stage capital requirements with an investment size ranging from GBP 0.15 to 2 million and also makes follow-on investments.	Finance
BenevolentAI Ltd. BenevolentAI Ltd. Packaged SoftwareTechnology Services Operates as a AI-enabled drug discovery company	Technology Services
BenevolentAI SA BenevolentAI SA Packaged SoftwareTechnology Services Develops AI drug discovery platform to accelerate biopharma drug discovery	Technology Services